| Date | Title | Description |
| 02.06.2025 | Acclaro Medical's $23 Million Leap: A New Era in Aesthetic Technology | In the world of medical technology, innovation is the lifeblood that fuels progress. Acclaro Medical, a Smithfield, Rhode Island-based company, has just secured a significant $23 million in Series B funding. This investment, led by Accelmed... |
| 29.05.2025 | Acclaro Medical Raises $23M in Series B Funding | Acclaro Medical, a Smithfield, RI-based medical technology company focused on developing solutions for patient care and medical practices, raised $23M in Series B funding.
The round was led by Accelmed Partners with participation from exist... |
| 29.05.2025 | Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology | Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market Growth
SMITHFIELD, R.I., May 29, 2025 /PRNewswire/ -- Acclaro Medical, a pioneering medical technol... |
| 14.05.2024 | Acclaro Medical Announces FDA Clearance of UltraClear® Cold Ablative Fractional 2910 nm Fiber Laser for Treatment of Benign Pigmented Lesions and Vascular Dyschromia | ~ The Global Market for Pigmented Lesion Treatment Is Expected to Reach $3.37 Billion in 2024, and $4.69 Billion by 20291
~ Leading Experts Will Illuminate Clinical Efficacy of UltraClear's New Indications at the Upcoming SCALE Symposium fo... |
| - | UltraClear | “UltraClear is the world's first cold fiber fractionated laser solution. FDA cleared and designed for all skin types.” |